Company profile
CeriBell, Inc.
NASDAQ: CBLL · Healthcare · Medical - Devices
#360 of 1,422 Healthcare companies by revenue74th-percentile growth
EA Score
49DFH 57DQ 35GM —SS 54
v0.1 · 55/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$95.1M
Rev growth YoY (TTM)
+33.7%
Net income (FY)
-$53.4M
Employees
327
as of 2026-08-11
Market cap
$732.3M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$89.1M$89.1M2025
Net income-$53.4M-$53.4M2025
Operating income-$58.4M-$58.4M2025
Total assets$195.8M$195.8M2025
Liabilities$40.5M$40.5M2025
Equity$155.3M$155.3M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product76%
Subscription24%
By geography
Not disclosed.
The read
What is CeriBell, Inc.’s revenue?
CeriBell, Inc. booked $89.1M in FY2025 revenue, growing 36% year over year — faster than most Healthcare companies we track, at a -60.0% net margin.
Peers · Healthcare
SIGA Technologies, Inc.73BPulmonx Corporation57CVaso Corporation68BBiodesix, Inc.57CCytokinetics, Incorporated59CFluent Corp.45DNeighbors
Santa Clara →Key facts
CEOXingjuan Chao
SectorHealthcare
IndustryMedical - Devices
HeadquartersSunnyvale, CA
ExchangeNASDAQ: CBLL
Employees327
IPO date2024-10-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.